PriceTargets.com logo

NASDAQ:STIM - Neuronetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.25
  • Forecasted Upside: 25.08 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$15.39 As of 03/3/2021 01:00 AM ET
▲ +0.36 (2.40%)
1 month | 3 months | 12 months
Get New Neuronetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STIM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.25
▲ +25.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Neuronetics in the last 3 months. The average price target is $19.25, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 25.08% upside from the last price of $15.39.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Neuronetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021Piper SandlerLower Price TargetOverweight$27.00 ➝ $25.00High
i
1/27/2021JMP SecuritiesBoost Price TargetOutperform$15.00 ➝ $23.00High
i
1/22/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by M. Kaczor at William Blair
1/21/2021BTIG ResearchBoost Price TargetBuy$14.00 ➝ $21.00High
i
Rating by Marie Thibault at BTIG Research
1/21/2021Piper SandlerBoost Price TargetOverweight$20.00 ➝ $27.00High
i
1/12/2021Piper SandlerBoost Price TargetOverweight$9.00 ➝ $20.00High
i
1/8/2021JMP SecuritiesBoost Price Target$10.00 ➝ $15.00High
i
12/7/2020BTIG ResearchBoost Price TargetBuy$10.00 ➝ $14.00High
i
Rating by Marie Thibault at BTIG Research
11/23/2020Piper SandlerBoost Price TargetOverweight$7.00 ➝ $9.00Medium
i
11/3/2020Canaccord GenuityReiterated RatingBuy$8.00High
i
10/26/2020Canaccord GenuityBoost Price TargetBuy$4.00 ➝ $8.00Low
i
10/6/2020BTIG ResearchBoost Price TargetBuy$6.00 ➝ $10.00High
i
Rating by Marie Thibault at BTIG Research
8/4/2020BTIG ResearchReiterated RatingBuy$6.00High
i
Rating by Marie Thibault at BTIG Research
5/6/2020Canaccord GenuityReiterated RatingBuy$4.00Low
i
5/5/2020William BlairDowngradeOutperform ➝ Market PerformMedium
i
Rating by M. Kaczor at William Blair
5/5/2020BTIG ResearchReiterated RatingBuy$6.00High
i
Rating by Marie Thibault at BTIG Research
4/9/2020BTIG ResearchLower Price Target$11.00 ➝ $6.00Medium
i
Rating by Marie Thibault at BTIG Research
4/9/2020Canaccord GenuityLower Price TargetBuy$7.00 ➝ $4.00High
i
3/4/2020Piper SandlerLower Price Target$14.00 ➝ $6.00Medium
i
3/4/2020Canaccord GenuityReiterated RatingBuyHigh
i
2/6/2020BTIG ResearchInitiated CoverageBuy$11.00High
i
12/6/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Matthew O'Brien at Piper Jaffray Companies
11/6/2019BTIG ResearchLower Price TargetBuy ➝ Average$11.00High
i
3/6/2019BTIG ResearchReiterated RatingBuy$25.00Low
i
3/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$35.00 ➝ $28.00High
i
11/7/2018BTIG ResearchReiterated RatingBuy$33.00High
i
8/16/2018BTIG ResearchReiterated RatingBuy$33.00Low
i
8/15/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Outperform$36.00 ➝ $40.00Low
i
8/15/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$33.00 ➝ $36.00Low
i
7/24/2018Canaccord GenuityInitiated CoverageBuy$33.00Low
i
7/23/2018JMP SecuritiesInitiated Coverage$26.02$36.00Low
i
7/23/2018BTIG ResearchInitiated CoverageBuy$33.00Low
i
7/23/2018William BlairInitiated CoverageOutperformLow
i
Rating by M. Kaczor at William Blair
7/23/2018Piper Jaffray CompaniesInitiated CoverageOverweightLow
i
(Data available from 3/4/2016 forward)
Neuronetics logo
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $15.39
$14.52
$15.70

50 Day Range

MA: $17.16
$11.67
$21.27

52 Week Range

Now: $15.39
$1.25
$22.43

Volume

632,524 shs

Average Volume

590,801 shs

Market Capitalization

$292.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Neuronetics?

The following equities research analysts have issued research reports on Neuronetics in the last year: BTIG Research, Canaccord Genuity, JMP Securities, Piper Sandler, William Blair, and Zacks Investment Research.
View the latest analyst ratings for STIM.

What is the current price target for Neuronetics?

4 Wall Street analysts have set twelve-month price targets for Neuronetics in the last year. Their average twelve-month price target is $19.25, suggesting a possible upside of 25.1%. Piper Sandler has the highest price target set, predicting STIM will reach $25.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $8.00 for Neuronetics in the next year.
View the latest price targets for STIM.

What is the current consensus analyst rating for Neuronetics?

Neuronetics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STIM will outperform the market and that investors should add to their positions of Neuronetics.
View the latest ratings for STIM.

What other companies compete with Neuronetics?

Other companies that are similar to Neuronetics include Cerus, LeMaitre Vascular, OrthoPediatrics, CryoLife, SI-BONE, Tactile Systems Technology, Orthofix Medical, AngioDynamics, OraSure Technologies, Intersect ENT, Surmodics, Antares Pharma, Pulse Biosciences, TransEnterix and Vapotherm.

How do I contact Neuronetics' investor relations team?

Neuronetics' physical mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company's listed phone number is (610) 640-4202 and its investor relations email address is [email protected] The official website for Neuronetics is www.neurostar.com.